The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): 4-year follow-up of CheckMate 9DW.
 
Peter Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - AstraZeneca; Bayer Schering Pharma; BMS GmbH & Co. KG; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca; Bayer Schering Pharma; Lilly; Roche/Genentech; Sirtex Medical
 
Bruno Sangro
Consulting or Advisory Role - AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb; Eisai; Roche/Genentech; Sanofi Pasteur; Sirtex Medical
Speakers' Bureau - AstraZeneca; Eisai; Roche
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Eisai; Roche; Sirtex Medical
 
Thomas Decaens
Honoraria - Abbvie; Gilead Sciences; MSD
Consulting or Advisory Role - AstraZeneca; Bayer; Becton Dickinson; Bristol-Myers Squibb; Guerbet; Ipsen; Roche; Sirtex Medical; TERUMO
Research Funding - ArQule (Inst); GenoScience Pharma (Inst); Guerbet (Inst)
Expert Testimony - Ipsen
 
Masatoshi Kudo
Honoraria - AstraZeneca; Chugai/Roche; Eisai
Consulting or Advisory Role - AstraZeneca; Chugai/Roche; Eisai
Research Funding - Eisai (Inst); GE Healthcare (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Leonardo Da Fonseca
No Relationships to Disclose
 
Hatim Karachiwala
Honoraria - Amgen; Astellas Pharma; AstraZeneca; BMSi; Eisai; Incyte; Ipsen; Merck; Roche Canada; Takeda
 
Joong-Won Park
No Relationships to Disclose
 
Edward Gane
No Relationships to Disclose
 
Matthias Pinter
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; MSD; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Roche (Inst)
(OPTIONAL) Uncompensated Relationships - European Association for the Study of the Liver (EASL)
 
David Tai
Consulting or Advisory Role - Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Eisai (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); Sirtex Medical (Inst)
 
Armando Santoro
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Gilead Sciences; Incyte; MSD; Pfizer; Sanofi; SERVIER
Speakers' Bureau - Abbvie; Amgen; ArQule; AstraZeneca; Bayer; BeiGene; BMS; Celgene; Eisai; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Roche; Sandoz; Servier; Takeda
 
Gonzalo Pizarro
Honoraria - Bayer; Pfizer
Speakers' Bureau - Bayer; Pfizer
Expert Testimony - Bayer; Pfizer
Travel, Accommodations, Expenses - Bayer; Pfizer
 
Michael Schenker
Research Funding - Abbvie; Amgen; Astellas Pharma; AstraZeneca; BeiGene; BIOVEN; Bristol-Myers Squibb; Clovis Oncology; Daiichi Sankyo; Eisai; Gilead Sciences; GlaxoSmithKline; Merck Serono; MSD; Mylan; Novartis; Pfizer; PharmaMar; Regeneron; Roche; Samsung; Sanofi
 
Qi Wang
Employment - Bristol Myers Squibb
Stock and Other Ownership Interests - Bristol Myers Squibb
Research Funding - Bristol Myers Squibb
 
Maria Jesus Jimenez Exposito
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Thomas Yau
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; MSD